Butyrylcholinesterase and γ-glutamyltransferase activities and oxidative stress markers are altered in metabolic syndrome, but are not affected by body mass index

Inflammation

Volumn 36, Issue 6, 2013, Pages 1539-1547

  De Bona, Karine S ^a   Bonfanti, Gabriela ^a   Bitencourt, Paula E R ^a   Cargnelutti, Lariane O ^a   Da Silva, Priscila S ^a   De Lucca, Leidiane ^a   Pimentel, Victor C ^a   Tatsch, Etiane ^a   Gonçalves, Thissiane L ^a   Premaor, Melissa ^a   Moresco, Rafael N ^a   Moretto, Maria Beatriz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

glutamyltransferase; body mass index; butyrylcholinesterase; metabolic syndrome; nitric oxide

Indexed keywords

ADENOSINE DEAMINASE; C REACTIVE PROTEIN; CHOLESTEROL; CHOLINESTERASE; DIPEPTIDYL PEPTIDASE IV; GAMMA GLUTAMYLTRANSFERASE; INSULIN; LIPID; NITRIC OXIDE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ENZYMATIC ASSAY; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PREVALENCE;

ADENOSINE DEAMINASE; BIOLOGICAL MARKERS; BODY MASS INDEX; BUTYRYLCHOLINESTERASE; C-REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL PEPTIDASE 4; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 84888203789     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9697-9     Document Type: Article

References (48)

1. Grundy, S.M., J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Jr Smith, J.A. Spertus, and F. Costa. 2005. American Heart Association; National Heart, Lung, and Blood Institute, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
2. Phillips, C., J. Lopez-Miranda, F. Perez-Jimenez, R. McManus, and H.M. Roche. 2006. Genetic and nutrient determinants of the metabolic syndrome. Current Opinion in Cardiology 21: 185-193.
3. Batsis, J.A., R.E. Nieto-Martinez, and F. Lopez-Jimenez. 2007. Metabolic syndrome: from global epidemiology to individualized medicine. Clinical Pharmacology and Therapeutics 82: 509-524.
4. Marquezine, G.F., C.M. Oliveira, A.C. Pereira, J.E. Krieger, and J.G. Mill. 2008. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. International Journal of Cardiology 129: 259-265.
5. Kuno, M., N. Seki, S. Tsujimoto, I. Nakanishi, T. Kinoshita, K. Nakamura, T. Terasaka, N. Nishio, A. Sato, and T. Fujii. 2006. Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. European Journal of Pharmacology 534: 241-249.
6. Conlon, B.A., and W.R. Law. 2004. Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clinical and Experimental Immunology 138: 14-20.
7. Prakash, M.S., S. Chennaiah, Y.S.R. Murthy, E. Anjaiah, S. Ananda Rao, and C. Suresh. 2006. Altered adenosine deaminase activity in type 2 diabetes mellitus. Journal Indian Academy of Clinical Medicine 7: 114-117.
8. Bopp, A., K.S. De Bona, L.P. Bellé, R.N. Moresco, and M.B. Moretto. 2009. Syzygium cumini inhibits adenosine deaminase activity and reduces glucose levels in hyperglycemic patients. Fundamental and Clinical Pharmacology 23: 501-507.
9. Kurtul, N., S. Pence, E. Akarsu, H. Kocoglu, Y. Aksoy, and H. Aksoy. 2004. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Médica 47: 33-35.
10. Dong, R.P., J. Kameoka, M. Hegen, T. Tanaka, Y. Xu, S.F. Schlossman, and C. Morimoto. 1996. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. The Journal of Immunology 156: 1349-1355.
11. Stancíková, M., Z. Lojda, J. Lukác, and M. Ruzicková. 1992. Dipeptidyl peptidase IV in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology 10: 381-385.
12. Lugari, R., A. Dei Cas, D. Ugolotti, A.L. Barilli, C. Camellini, G.C. Ganzerla, A. Luciani, B. Salerni, F. Mittenperger, S. Nodari, A. Gnudi, and R. Zandomeneghi. 2004. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Hormone and Metabolism Research 36: 111-115.
13. Ryskjaer, J., C.F. Deacon, R.D. Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsbøll. 2006. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology 155: 485-493.
14. De Bona, K.S., G. Bonfanti, L.O. Cargnelutti, P.E. Bitencourt, P.S. da Silva, R. Ceolin, V.C. Pimentel, and M.B. Moretto. 2012. Lymphocytic enzymes and lipid peroxidation in patients with metabolic syndrome. Clinical Biochemistry 45: 1081-1085.
15. Randell, E.W., M.S. Mathews, H. Zhang, J.S. Seraj, and G. Sun. 2005. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clinical Biochemistry 38: 799-805.
16. Abbott, C.A., M.I. Mackness, S. Kumar, A.O. Olukoga, C. Gordon, S. Arrol, D. Bhatnagar, A.J. Boulton, and P.N. Durrington. 1993. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clinical Science 85: 77-81.
17. Alcantara, V.M., E.A. Chautard-Freire-Maia, M. Scartezini, M.S. Cerci, K. Braun-Prado, and G. Picheth. 2002. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation 62: 399-404.
18. Vaidya, D., M. Szklo, M. Cushman, P. Holvoet, J. Polak, H. Bahrami, N.S. Jenny, and P. Ouyang. 2011. Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosis. European Journal of Clinical Nutrition 65: 818-825.
19. Sun, Y.X., S.J. Hu, X.H. Zhang, J. Sun, C.H. Zhu, and Z.J. Zhang. 2006. Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders. Zhejiang Da Xue Xue Bao. Yi Xue Ban 35: 315-318.
20. Zahedi Asl, S., A. Ghasemi, and F. Azizi. 2008. Serum nitric oxide metabolites in subjects with metabolic syndrome. Clinical Biochemistry 41: 1342-1347.
21. Koh, K.K., M.J. Quon, S.H. Han, W.J. Chung, J.A. Kim, and E.K. Shin. 2006. Vascular and metabolic effects of candesartan: insights from therapeutic interventions. Journal of Hypertension. Supplement 24: 31-38.
22. Assumpção, C.R., T.M.C. Brunini, C. Matsuura, A.C. Resende, and A.C. Mendes- Ribeiro. 2008. Impact of the l-arginine-nitric oxide pathway and oxidative stress on the pathogenesis of the metabolic syndrome. Open Biochemistry Journal 2: 108-115.
23. Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of concentration of low-density lipoprotein in plasma, without use of preparative ultracentrifuge. Clinical Chemistry 18: 499-502.
24. Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
25. Giusti, G., and C. Gakis. 1971. Temperature conversion factors, activation energy, relative substrate specificity and optimum pH of adenosine deaminase from human serum and tissues. Enzyme 12: 417-425.
26. Jarmołowska, B., K. Bielikowicz, M. Iwan, K. Sidor, E. Kostyra, and M. Kaczmarski. 2007. Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergy. Peptides 28: 678-682.
27. Ellman, G.C., K.D. Courtney, V. Andres, and R.M. Feather- Stone. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 7: 88-95.
28. Tatsch, E., G.V. Bochi, S. Pereira Rda, H. Kober, V.A. Agertt, M.M. de Campos, P. Gomes, M.M. Duarte, and R.N. Moresco. 2011. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clinical Biochemistry 44: 348-350.
29. Boyne, A.F., and G.L. Ellman. 1972. A methodology for analysis of tissue sulfhydryl components. Analytical Biochemistry 46: 639-653.
30. Jacqes-Silva, M.C., C.W. Nogueira, L.C. Broch, E.M. Flores, and J.B. Rocha. 2001. Diphenyl diselenide and ascorbic acid changes deposition of selenium and brain of mice. Phamacology and Toxicology 88: 119-125.
31. Galley, H., M.J. Davies, and N.R. Webster. 1996. Ascorbil radical formation in patients with sepsis: effects of ascorbate loading. Free Radical Biology and Medicine 20: 139-143.
32. Lapenna, D., G. Ciofani, S.D. Pierdomenico, M.A. Giamberardino, and F. Cuccurullo. 2001. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radical Biology and Medicine 31: 331-335.
33. Festa, A., R. D'Agostino Jr., G. Howard, L. Mykkänen, R.P. Tracy, and S.M. Haffner. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47.
34. Ridker, P.M., J.E. Buring, N.R. Cook, and N. Rifai. 2003. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397.
35. Haas, M.J., and A.D. Mooradian. 2011. Inflammation, high-density lipoprotein and cardiovascular dysfunction. Current Opinion in Infectious Diseases 24: 265-272.
36. Elks, C.M., and J. Francis. 2010. Central adiposity, systemic inflammation, and the metabolic syndrome. Current Hypertension Reports 12: 99-104.
37. Magarian, E.O., and A.J. Dietz. 1987. Correlation of cholinesterase with serum lipids and lipoproteins. The Journal of Clinical Pharmacology 27: 819-820.
38. Sridhar, G.R., G. Nirmala, A. Apparao, A.S. Madhavi, S. Sreelatha, J.S. Rani, and P. Vijayalakshmi. 2005. Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipids in Health and Disease 8: 4-18.
39. Kalman, J., A. Juhasz, Z. Rakonczay, G. Abrahám, M. Zana, K. Boda, T. Farkas, B. Penke, and Z. Janka. 2004. Increase serum butyrylcholinesterase activity in type IIb hyperlipidemic patients. Life Science 75: 1195-1204.
40. Meghji, P. 1991. Adenosine production and metabolism. In Adenosine in the nervous system, ed. T. Stone, 25-42. London: Academic.
41. Rosenstock, J., M.A. Baron, S. Dejager, D. Mills, and A. Schweizer. 2007. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30: 217-223.
42. Bozbaş, H., A. YIldIrIr, E. Karaçaǧlar, O. Demir, T. Ulus, S. Eroǧlu, A. AydInalp, B. Ozin, and H. Müderrisoǧlu. 2011. Increased serum gamma glutamyltransferase activity in patients with metabolic syndrome. Türk Kardiyoloji Derneǧi Arşivi 39: 122-128.
43. Giral, P., N. Jacob, C. Dourmap, B. Hansel, A. Carrié, E. Bruckert, X. Girerd, and M.J. Chapman. 2008. Elevated gamma-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 587-593.
44. Vincent, H.K., and A.G. Taylor. 2006. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. International Journal of Obesity (Lond) 30: 400-418.
45. Doi, Y., Y. Kiyohara, M. Kubo, T. Ninomiya, Y. Wakugawa, K. Yonemoto, M. Iwase, and M. Iida. 2005. Elevated C-reactive protein is a predictor of diabetes in a general Japanese population: the Hisayama study. Diabetes Care 28: 2497-2500.
46. Ford, E.S. 2003. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168: 351-358.
47. Amiri, F. 2009. Metabolic syndrome, insulin resistance and oxidative stress: adding insights to improve cardiovascular prevention. Journal of Hypertension 27: 1352-1354.
48. Pischon, T., F.B. Hu, K.M. Rexrode, J.C. Girman, A.E. Manson, and E.B. Rimm. 2008. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 197: 392-399.